A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.

US FDA Commissioner Scott Gottlieb, who seems to be the Trump Administration’s advance man on prescription drug pricing policy these days, recently signaled there may be interest in a more fundamental approach to solving the problem of rebates – making them illegal.

During a speech to the Food and Drug Law Institute annual meeting May 3, he referred to the problem of...

More from Pricing Debate

More from Market Access